Cilengitide

Drug Profile

Cilengitide

Alternative Names: Cilcane; EMD-121974; EMD-85189; ICE1

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Merck KGaA; The Scripps Research Institute; University of Munich
  • Developer Iceni Pharmaceuticals; Martin Luther University of Halle-Wittenberg; Merck KGaA; National Cancer Institute (USA)
  • Class Antineoplastics; Cyclic peptides; Small molecules; Venoms
  • Mechanism of Action Angiogenesis inhibitors; Integrin alphaVbeta3 antagonists; Integrin alphaVbeta5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma
  • Discontinued Glioblastoma; Head and neck cancer; Lymphoma; Non-small cell lung cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 25 May 2016 Preclinical trials in Multiple myeloma in United Kingdom (unspecified route)
  • 25 May 2016 Iceni Pharmaceuticals plans a phase II trial for Multiple myeloma (Combination therapy, Late-stage disease)
  • 01 Aug 2013 Merck completes the phase III CENTRIC trial in Glioblastoma (Combination therapy, Newly diagnosed) in US, Belgium, Austria, Germany, France, Spain, Italy, Slovakia, Hungary, Czech Republic, Netherlands, India, and the UK (NCT00689221)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top